Bodyport · Nov 2024
Bodyport added Jim Pursley to its board as it described a move into commercialization and growth.
Predicting and preventing heart disease.
Company research
Public company, workplace, funding, and market signals
Overview
Bodyport is a San Francisco-based digital therapeutics company focused on heart-failure / fluid-management monitoring. Its core product is the FDA-cleared Bodyport Cardiac Scale plus Congestion Index software, which combines hemodynamic biomarkers, a clinical portal, and a patient app to support remote care. Public leadership data are partly stale: older company pages still refer to John Lipman as CEO, while his 2026 LinkedIn profile lists him as a current Bodyport board member after Nov. 2025.
Primary product
Bodyport Cardiac Scale + Congestion Index platform
Founded
2015
Headquarters
120 2nd Street, 2nd Floor, San Francisco, CA 94105, United States
Team size
10-20
Work style
Onsite
Industry
Hospitals and Health Care
Sub-industry
Open Positions
0 jobs at Bodyport
No open positions
Check back later for new openings